Component: (Network and Table)
Network
00100 - Statement - CONSOLIDATED BALANCE SHEETS
(http://www.adaptimmune.com/role/StatementConsolidatedBalanceSheets)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001621227 (http://www.sec.gov/CIK)
CONDENSED CONSOLIDATED BALANCE SHEETSPeriod [Axis]
2016-12-31
2015-12-31
2015-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS
 
 
 
Assets [Abstract]
 
 
 
Current assets
 
 
 
Cash and cash equivalents
158,779,000  
194,263,000  
229,046,000  
Short-term deposits
22,694,000  
54,620,000  
55,292,000  
Accounts receivable, net of allowance for doubtful accounts of $-, $- and $- (including amounts due from related parties of $-, $2 and $3)
1,480,000  
744,000  
4,000  
Other current assets and prepaid expenses (including current portion of clinical materials)
15,798,000  
13,420,000  
10,740,000  
Total current assets
198,751,000  
 
263,047,000  
 
295,082,000  
 
Restricted cash
4,017,000  
4,508,000  
 
Clinical materials
2,580,000  
4,736,000  
 
Property, plant and equipment, net
27,899,000  
13,225,000  
5,393,000  
Intangibles, net
1,268,000  
305,000  
178,000  
Total assets
234,515,000  
 
285,821,000  
 
300,653,000  
 
Liabilities and Equity [Abstract]
 
 
 
Current liabilities
 
 
 
Accounts payable (including amounts due to related parties of $326, $- and $143)
11,350,000  
7,884,000  
1,982,000  
Accrued expenses and other accrued liabilities (including amounts due to related parties of $39, $288 and $2)
17,528,000  
7,518,000  
3,877,000  
Deferred revenue
11,392,000  
12,487,000  
20,906,000  
Total current liabilities
40,270,000  
 
27,889,000  
 
26,765,000  
 
Deferred revenue, non-current
24,962,000  
22,939,000  
14,885,000  
Accrued expenses, non-current
3,141,000  
  
Total liabilities
68,373,000  
 
50,828,000  
 
41,650,000  
 
Contingencies and commitments - Note 8
xsi:nil  
xsi:nil  
xsi:nil  
Stockholders' Equity
 
 
 
Common stock - Ordinary shares par value GBP 0.001, 574,711,900 authorized and 424,775,092 issued and outstanding (December 31, 2015 and June 30, 2015: 574,711,900 authorized and 424,711,900 issued and outstanding)
683,000  
682,000  
682,000  
Additional paid in capital
341,200,000  
332,363,000  
328,795,000  
Accumulated other comprehensive loss
(14,249,000) 
(8,139,000) 
(3,561,000) 
Accumulated deficit
(161,492,000) 
(89,913,000) 
(66,913,000) 
Total stockholders' equity
166,142,000  
 
234,993,000  
 
259,003,000  
 
Total liabilities and stockholders' equity
234,515,000  
 
285,821,000  
 
300,653,000